Million-dollar investment from Eir Ventures will bring Swedish cancer company to clinic

Life science fund Eir Ventures leads a SEK 45m (USD 4.8m) financing round meant to bring Swedish cancer company Strike Pharma’s first drug candidate closer to human clinical trials.
Stephan Christgau (left), co-founder and partner at Eir Ventures | Photo: Nikolai Linares
Stephan Christgau (left), co-founder and partner at Eir Ventures | Photo: Nikolai Linares
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen

Swedish biotech firm Strike Pharma has secured financial backing to further advance its antibody-based technology for the development of individualized immunotherapeutic treatments for cancer and to bring its first candidate to clinic.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading